Novel human mPGES-1 inhibitors identified through structure-based virtual screening.

[1]  O. Werz,et al.  Pharmacophore Modeling and Virtual Screening for Novel Acidic Inhibitors of Microsomal Prostaglandin E2 Synthase-1 (mPGES-1) , 2011, Journal of medicinal chemistry.

[2]  G. Bifulco,et al.  Structure-based discovery of inhibitors of microsomal prostaglandin E2 synthase-1, 5-lipoxygenase and 5-lipoxygenase-activating protein: promising hits for the development of new anti-inflammatory agents. , 2011, Journal of medicinal chemistry.

[3]  A. Hamza,et al.  Understanding microscopic binding of human microsomal prostaglandin E synthase-1 (mPGES-1) trimer with substrate PGH2 and cofactor GSH: insights from computational alanine scanning and site-directed mutagenesis. , 2010, The journal of physical chemistry. B.

[4]  G. Schneider,et al.  Nonacidic inhibitors of human microsomal prostaglandin synthase 1 (mPGES 1) identified by a multistep virtual screening protocol. , 2010, Journal of medicinal chemistry.

[5]  David C. Thompson,et al.  Comparison of Several Molecular Docking Programs: Pose Prediction and Virtual Screening Accuracy , 2009, J. Chem. Inf. Model..

[6]  Chang-Guo Zhan,et al.  Determination of the structure of human phosphodiesterase-2 in a bound state and its binding with inhibitors by molecular modeling, docking, and dynamics simulation. , 2009, The journal of physical chemistry. B.

[7]  Ralf Morgenstern,et al.  Structural basis for induced formation of the inflammatory mediator prostaglandin E2 , 2008, Proceedings of the National Academy of Sciences.

[8]  Chang-Guo Zhan,et al.  Understanding microscopic binding of human microsomal prostaglandin E synthase-1 with substrates and inhibitors by molecular modeling and dynamics simulation. , 2008, The journal of physical chemistry. B.

[9]  J. Mancini,et al.  Microsomal prostaglandin E2 synthase-1 (mPGES-1): a novel anti-inflammatory therapeutic target. , 2008, Journal of medicinal chemistry.

[10]  J. Venhorst,et al.  Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. , 2008, Journal of medicinal chemistry.

[11]  D. Case,et al.  Rescoring docking hit lists for model cavity sites: predictions and experimental testing. , 2008, Journal of molecular biology.

[12]  John W. Liebeschuetz,et al.  Evaluating docking programs: keeping the playing field level , 2008, J. Comput. Aided Mol. Des..

[13]  Tao Zhang,et al.  A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells , 2008, Molecular Cancer Therapeutics.

[14]  Ralf Morgenstern,et al.  Membrane Prostaglandin E Synthase-1: A Novel Therapeutic Target , 2007, Pharmacological Reviews.

[15]  Chang-Guo Zhan,et al.  The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. , 2007, Chemistry & biology.

[16]  G. Schneider,et al.  Identification of natural-product-derived inhibitors of 5-lipoxygenase activity by ligand-based virtual screening. , 2007, Journal of medicinal chemistry.

[17]  P. Hawkins,et al.  Comparison of shape-matching and docking as virtual screening tools. , 2007, Journal of medicinal chemistry.

[18]  Imran Siddiqi,et al.  Solvated Interaction Energy (SIE) for Scoring Protein-Ligand Binding Affinities, 1. Exploring the Parameter Space , 2007, J. Chem. Inf. Model..

[19]  J. Gready,et al.  Combining docking and molecular dynamic simulations in drug design , 2006, Medicinal research reviews.

[20]  Shizuo Akira,et al.  Microsomal prostaglandin E synthase-1 is a critical factor of stroke-reperfusion injury. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[21]  K. Scholich,et al.  Is mPGES-1 a promising target for pain therapy? , 2006, Trends in pharmacological sciences.

[22]  S. Abramson,et al.  Prostaglandin E2 synthesis and secretion: the role of PGE2 synthases. , 2006, Clinical immunology.

[23]  Chang-Guo Zhan,et al.  Structural and functional characterization of human microsomal prostaglandin E synthase-1 by computational modeling and site-directed mutagenesis. , 2006, Bioorganic & medicinal chemistry.

[24]  Ying Yu,et al.  Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. , 2006, The Journal of clinical investigation.

[25]  A. Hamza,et al.  How can (-)-epigallocatechin gallate from green tea prevent HIV-1 infection? Mechanistic insights from computational modeling and the implication for rational design of anti-HIV-1 entry inhibitors. , 2006, The journal of physical chemistry. B.

[26]  Makoto Murakami,et al.  Prostaglandin E synthase, a terminal enzyme for prostaglandin E2 biosynthesis. , 2005, Journal of biochemistry and molecular biology.

[27]  N. Méthot,et al.  Inhibitors of the inducible microsomal prostaglandin E2 synthase (mPGES-1) derived from MK-886. , 2005, Bioorganic & medicinal chemistry letters.

[28]  Tom L. Blundell,et al.  Keynote review: Structural biology and drug discovery , 2005 .

[29]  J. A. Grant,et al.  A shape-based 3-D scaffold hopping method and its application to a bacterial protein-protein interaction. , 2005, Journal of medicinal chemistry.

[30]  Brian K. Shoichet,et al.  Virtual screening of chemical libraries , 2004, Nature.

[31]  Robert J. Jilek,et al.  "Lead hopping". Validation of topomer similarity as a superior predictor of similar biological activities. , 2004, Journal of medicinal chemistry.

[32]  J. Bajorath,et al.  Docking and scoring in virtual screening for drug discovery: methods and applications , 2004, Nature Reviews Drug Discovery.

[33]  M. Gilson,et al.  Calculation of cyclodextrin binding affinities: energy, entropy, and implications for drug design. , 2004, Biophysical journal.

[34]  H. Fahmi,et al.  mPGES-1 as a novel target for arthritis , 2004, Current opinion in rheumatology.

[35]  Makoto Murakami,et al.  Reduced Pain Hypersensitivity and Inflammation in Mice Lacking Microsomal Prostaglandin E Synthase-1* , 2004, Journal of Biological Chemistry.

[36]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[37]  Hiroko Oshima,et al.  Hyperplastic gastric tumors induced by activated macrophages in COX‐2/mPGES‐1 transgenic mice , 2004, The EMBO journal.

[38]  Anders Blomqvist,et al.  Microsomal prostaglandin E synthase-1 is the central switch during immune-induced pyresis , 2003, Nature Neuroscience.

[39]  B. Levy,et al.  Success of prostaglandin E2 in structure–function is a challenge for structure-based therapeutics , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Giulio Rastelli,et al.  Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors. , 2003, Journal of medicinal chemistry.

[41]  J. Lapointe,et al.  Impaired inflammatory and pain responses in mice lacking an inducible prostaglandin E synthase , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[42]  Makoto Murakami,et al.  Potential Role of Microsomal Prostaglandin E Synthase-1 in Tumorigenesis* , 2003, Journal of Biological Chemistry.

[43]  Renxiao Wang,et al.  Comparative evaluation of 11 scoring functions for molecular docking. , 2003, Journal of medicinal chemistry.

[44]  Yves Bureau,et al.  Microsomal Prostaglandin E Synthase-1 Is a Major Terminal Synthase That Is Selectively Up-Regulated During Cyclooxygenase-2-Dependent Prostaglandin E2 Production in the Rat Adjuvant-Induced Arthritis Model , 2003, The Journal of Immunology.

[45]  Jonas Boström,et al.  Assessing the performance of OMEGA with respect to retrieving bioactive conformations. , 2003, Journal of molecular graphics & modelling.

[46]  Makoto Murakami,et al.  Prostaglandin E synthase. , 2002, Prostaglandins & other lipid mediators.

[47]  Shizuo Akira,et al.  Lipopolysaccharide-Dependent Prostaglandin E2 Production Is Regulated by the Glutathione-Dependent Prostaglandin E2 Synthase Gene Induced by the Toll-Like Receptor 4/MyD88/NF-IL6 Pathway1 , 2002, The Journal of Immunology.

[48]  B. Shoichet,et al.  Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B. , 2002, Journal of medicinal chemistry.

[49]  D. Riendeau,et al.  Inhibition of inducible prostaglandin E2 synthase by 15-deoxy-Δ12,14-prostaglandin J2 and polyunsaturated fatty acids , 2002 .

[50]  Jonas Boström,et al.  Reproducing the conformations of protein-bound ligands: A critical evaluation of several popular conformational searching tools , 2001, J. Comput. Aided Mol. Des..

[51]  R Abagyan,et al.  High-throughput docking for lead generation. , 2001, Current opinion in chemical biology.

[52]  M Rarey,et al.  Detailed analysis of scoring functions for virtual screening. , 2001, Journal of medicinal chemistry.

[53]  D. Riendeau,et al.  Cloning, Expression, and Up-regulation of Inducible Rat Prostaglandin E Synthase during Lipopolysaccharide-induced Pyresis and Adjuvant-induced Arthritis* , 2001, The Journal of Biological Chemistry.

[54]  P. Jakobsson,et al.  Coordinate up- and down-regulation of glutathione-dependent prostaglandin E synthase and cyclooxygenase-2 in A549 cells. Inhibition by NS-398 and leukotriene C4. , 2000, European journal of biochemistry.

[55]  Makoto Murakami,et al.  Regulation of Prostaglandin E2 Biosynthesis by Inducible Membrane-associated Prostaglandin E2 Synthase That Acts in Concert with Cyclooxygenase-2* , 2000, The Journal of Biological Chemistry.

[56]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[57]  R. Cramer,et al.  Prospective identification of biologically active structures by topomer shape similarity searching. , 1999, Journal of medicinal chemistry.

[58]  Enrico O. Purisima,et al.  Fast summation boundary element method for calculating solvation free energies of macromolecules , 1998, J. Comput. Chem..

[59]  G. V. Paolini,et al.  Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes , 1997, J. Comput. Aided Mol. Des..

[60]  Gennady M Verkhivker,et al.  Molecular recognition of the inhibitor AG-1343 by HIV-1 protease: conformationally flexible docking by evolutionary programming. , 1995, Chemistry & biology.

[61]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[62]  P A Kollman,et al.  Molecular dynamics studies of a DNA‐binding protein: 2. An evaluation of implicit and explicit solvent models for the molecular dynamics simulation of the Escherichia coli trp repressor , 1992, Protein science : a publication of the Protein Society.

[63]  I. Kuntz,et al.  Automated docking with grid‐based energy evaluation , 1992 .

[64]  Brian K. Shoichet,et al.  Molecular docking using shape descriptors , 1992 .

[65]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[66]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[67]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[68]  Makoto Murakami,et al.  Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. , 2004, Progress in lipid research.

[69]  J. A. Grant,et al.  Gaussian docking functions. , 2003, Biopolymers.

[70]  S. Harvey.  Treatment of electrostatic effects in macromolecular modeling , 1989, Proteins.